Patients as Advocates – Selin Kurnaz

In this episode, Naji Gehchan welcomes Selin Kurnaz, CEO and co-founder of Massive Bio, a health tech company using AI and data-driven solutions to expand access to cancer clinical trials. Selin shares her personal journey from a structured career in engineering and private equity to founding Massive Bio after her family’s experience with cancer. What started as a side project quickly became her full-time mission, as she realized the immense challenges and dedication required to drive change in healthcare. Since 2015, she has led Massive Bio to impact over 160,000 patients worldwide, with a focus on underserved communities and equitable access to clinical trials.

Selin highlights the importance of applying engineering principles to clinical operations, particularly in solving the long-standing challenge of patient recruitment in oncology trials. By combining systematic problem-solving with regulatory knowledge, Massive Bio addresses inefficiencies across the patient enrollment journey—identification, pre-screening, and last-mile enrollment. She explains how AI enables scalability, reducing the time it takes to match patients with clinical trials from months to minutes. This approach not only empowers patients to advocate for themselves but also helps physicians and pharma companies accelerate drug development, creating both individual and population-level impact.

Discussing leadership and growth, Selin emphasizes resilience, teamwork, and the importance of early adopters in driving healthcare innovation. She speaks candidly about the challenges women face in senior roles within health tech and the need for true meritocracy. At Massive Bio, she fosters a flat, mission-driven culture where every team member feels empowered and connected to the purpose of improving patients’ lives. Her closing advice to healthcare leaders is to remain resilient, embrace humility, and stay grounded—focusing on what truly matters: health, team, and impact.

"I’m not seeking fairness in life, but success in the unfairness of life."

MEET OUR GUEST Selin Kurnaz, CEO and co-founder of Massive Bio, a health tech company improving access to cancer clinical trials through AI and data-driven solutions.

Selin Kurnaz is the CEO and co-founder of Massive Bio, a health tech company improving access to cancer clinical trials through AI and data-driven solutions. She holds a PhD in Mechanical Engineering and brings over a decade of experience in life sciences strategy and operations. Inspired by her family’s cancer journey, Selin launched Massive Bio in 2015 to make cutting-edge treatments more accessible, particularly in underserved communities. Under her leadership, the company has onboarded over 160,000 patients and built a global network of sites, partners, and advocates. Selin is also a recognized voice for women in tech and digital health innovation.

About Massive Bio: Massive Bio is a healthcare technology company using AI to match cancer and rare disease patients with clinical trials and optimize drug use for better outcomes. Founded to address the barriers patients face in accessing advanced treatments, the platform simplifies and personalizes the clinical trial journey. With over 160,000 patients onboarded and partnerships with top pharma companies across 17 countries, Massive Bio is transforming oncology care. Its solutions reduce inefficiencies, accelerate drug development, and improve treatment access globally. The company is now expanding beyond trial matching into broader oncology services to become a leading data-driven cancer care platform.